SEC Form 4 · accession 0001209191-15-084729
Adverum Biotechnologies, Inc. · ADVM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul B Cleveland
Officer — President and CEO · Director
Period of report
Dec 9, 2015
Accepted (ET)
Dec 11, 2015 · 4:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501756
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.04 | Dec 9, 2015 | A | 910,000 | A | — | Dec 9, 2025 | Common Stock | 910,000 | 910,000 | D |
Explanation of responses
- F1Twenty-Five Percent (25%) of the total shares subject to the option vest and become exercisable on the first anniversary of December 9, 2015 (the "Vesting Commencement Date") and 1/48 of the total shares subject to the option shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates, so that all of the shares subject to the option are vested and exercisable on the fourth anniversary of the Vesting Commencement Date.